Category

Treatments

COMPEL Study Shows Continuing Osimertinib Treatment Through Progression with the Addition of Chemotherapy Improves Progression-Free Survival in EGFR-Mutated NSCLC ResearchTreatments

COMPEL Study Shows Continuing Osimertinib Treatment Through Progression with the Addition of Chemotherapy Improves Progression-Free Survival in EGFR-Mutated NSCLC

*September 2025* A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy. The study showed that continuing osimertinib with the addition…
Hannah Burson
March 11, 2026
Onc Live
FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC ResearchTreatments

FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC

*September 2025* Key Takeaways Iza-bren targets EGFR and HER3, showing potential in treating EGFR-mutant NSCLC after progression on EGFR TKI and platinum-based chemotherapy. The FDA's breakthrough therapy designation highlights iza-bren's potential to improve clinical outcomes for previously treated EGFR-mutated NSCLC patients. Clinical trials focus on determining the recommended phase 2…
laurabbook@gmail.com
February 20, 2026
Science Direct
ResearchTreatments

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma

*June 2025* Abstract Introduction Dysregulated MET signaling, such as MET overexpression or MET amplification (METamp), is a important mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant lung adenocarcinoma (LUAD). Combination therapy with EGFR TKIs and MET TKIs has revealed efficacy in these patients. This study…
laurabbook@gmail.com
November 20, 2025
Journal of Thoracic Disease
ResearchTreatments

Efficacy evaluation of tyrosine kinase inhibitors for advanced non-small cell lung cancer patients with leptomeningeal metastasis

*May 2025* Background: Leptomeningeal metastasis (LM) is an infrequent and challenging site of metastasis in patients with non-small cell lung cancer (NSCLC). Currently, there is no standardized treatment protocol or consensus for managing NSCLC patients with LM. This study aims to comprehensively evaluate the efficacy and safety of targeted therapy in…
laurabbook@gmail.com
November 20, 2025
OncLive
ResearchTreatments

First-Line Osimertinib Plus Chemo Boosts OS in EGFR+ NSCLC

*July 2025* First-line treatment with the combination of osimertinib (Tagrisso) in combination with chemotherapy led to a statistically significant and clinically meaningful improvement in overall survival (OS) compared with osimertinib alone in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to data from…
laurabbook@gmail.com
November 20, 2025
OncLive
ResearchTreatments

FDA Grants Fast Track Designation to Next-Generation HER3-Directed ADC for EGFR+ Advanced NSCLC

*July 2025* The FDA has granted fast track designation to the next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310 for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) harboring an EGFR exon 19 deletion or exon 21 L858R mutation who experienced disease progression on or after…
laurabbook@gmail.com
November 20, 2025
OncLive
ResearchTreatments

Understanding Underlying Resistance Mechanisms is Vital for Guiding Treatment Selection Post-Osimertinib in EGFR+ NSCLC

*July 2025* In a presentation at the 26th Annual International Lung Cancer Congress, Heather Wakelee, MD, highlighted therapeutic avenues in the second line after the development of resistance to first-line osimertinib (Tagrisso) or combination therapies for patients with non–small cell lung cancer (NSCLC) harboring EGFR mutations.1 These included secondary mutation–targeted therapies; chemotherapy-based treatment, including the…
laurabbook@gmail.com
November 20, 2025